BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33822623)

  • 1. Discovery and Optimization of 2
    Rohde JM; Karavadhi S; Pragani R; Liu L; Fang Y; Zhang W; McIver A; Zheng H; Liu Q; Davis MI; Urban DJ; Lee TD; Cheff DM; Hollingshead M; Henderson MJ; Martinez NJ; Brimacombe KR; Yasgar A; Zhao W; Klumpp-Thomas C; Michael S; Covey J; Moore WJ; Stott GM; Li Z; Simeonov A; Jadhav A; Frye S; Hall MD; Shen M; Wang X; Patnaik S; Boxer MB
    J Med Chem; 2021 Apr; 64(8):4913-4946. PubMed ID: 33822623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
    Reinbold R; Hvinden IC; Rabe P; Herold RA; Finch A; Wood J; Morgan M; Staudt M; Clifton IJ; Armstrong FA; McCullagh JSO; Redmond J; Bardella C; Abboud MI; Schofield CJ
    Nat Commun; 2022 Aug; 13(1):4785. PubMed ID: 35970853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
    Caravella JA; Lin J; Diebold RB; Campbell AM; Ericsson A; Gustafson G; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Kershaw M; Yao L; Toms AV; Barr KJ; Dinsmore CJ; Walker D; Ashwell S; Lu W
    J Med Chem; 2020 Feb; 63(4):1612-1623. PubMed ID: 31971798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
    Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
    Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
    Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
    J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
    Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
    Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Chen Z; Wan H; Tang S; Ye Y; Xu Y; Jiang L; Ding J; Geng M; Huang M; Huang Y
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3808-3812. PubMed ID: 30413349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development of IDH1 inhibitors for cancer therapy.
    Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
    Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
    Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
    Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
    Jones S; Ahmet J; Ayton K; Ball M; Cockerill M; Fairweather E; Hamilton N; Harper P; Hitchin J; Jordan A; Levy C; Lopez R; McKenzie E; Packer M; Plant D; Simpson I; Simpson P; Sinclair I; Somervaille TC; Small H; Spencer GJ; Thomson G; Tonge M; Waddell I; Walsh J; Waszkowycz B; Wigglesworth M; Wiseman DH; Ogilvie D
    J Med Chem; 2016 Dec; 59(24):11120-11137. PubMed ID: 28002956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
    Wen F; Gui G; Wang X; Qin A; Ma T; Chen H; Li C; Zha X
    J Med Chem; 2024 Jun; 67(11):8667-8692. PubMed ID: 38651495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
    Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
    J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
    Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
    Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivosidenib in Isocitrate Dehydrogenase 1
    Mellinghoff IK; Ellingson BM; Touat M; Maher E; De La Fuente MI; Holdhoff M; Cote GM; Burris H; Janku F; Young RJ; Huang R; Jiang L; Choe S; Fan B; Yen K; Lu M; Bowden C; Steelman L; Pandya SS; Cloughesy TF; Wen PY
    J Clin Oncol; 2020 Oct; 38(29):3398-3406. PubMed ID: 32530764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
    Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
    Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.